» Articles » PMID: 39598507

Drug Release Via Ultrasound-Activated Nanocarriers for Cancer Treatment: A Review

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 Nov 27
PMID 39598507
Authors
Affiliations
Soon will be listed here.
Abstract

Conventional cancer chemotherapy often struggles with safely and effectively delivering anticancer therapeutics to target tissues, frequently leading to dose-limiting toxicity and suboptimal therapeutic outcomes. This has created a need for novel therapies that offer greater efficacy, enhanced safety, and improved toxicological profiles. Nanocarriers are nanosized particles specifically designed to enhance the selectivity and effectiveness of chemotherapy drugs while reducing their toxicity. A subset of drug delivery systems utilizes stimuli-responsive nanocarriers, which enable on-demand drug release, prevent premature release, and offer spatial and temporal control over drug delivery. These stimuli can be internal (such as pH and enzymes) or external (such as ultrasound, magnetic fields, and light). This review focuses on the mechanics of ultrasound-induced drug delivery and the various nanocarriers used in conjunction with ultrasound. It will also provide a comprehensive overview of key aspects related to ultrasound-induced drug delivery, including ultrasound parameters and the biological effects of ultrasound waves.

Citing Articles

Alginate Hydrogel Beads with a Leakproof Gold Shell for Ultrasound-Triggered Release.

Flowers M, Paulsen A, Kaiser C, Tuma A, Lim H, Ogle B Pharmaceutics. 2025; 17(1).

PMID: 39861779 PMC: 11768098. DOI: 10.3390/pharmaceutics17010133.

References
1.
Cao Y, Chen Y, Yu T, Guo Y, Liu F, Yao Y . Drug Release from Phase-Changeable Nanodroplets Triggered by Low-Intensity Focused Ultrasound. Theranostics. 2018; 8(5):1327-1339. PMC: 5835939. DOI: 10.7150/thno.21492. View

2.
Tharkar P, Varanasi R, Wong W, Jin C, Chrzanowski W . Nano-Enhanced Drug Delivery and Therapeutic Ultrasound for Cancer Treatment and Beyond. Front Bioeng Biotechnol. 2019; 7:324. PMC: 6883936. DOI: 10.3389/fbioe.2019.00324. View

3.
Lin C, Javadi M, Belnap D, Barrow J, Pitt W . Ultrasound sensitive eLiposomes containing doxorubicin for drug targeting therapy. Nanomedicine. 2013; 10(1):67-76. DOI: 10.1016/j.nano.2013.06.011. View

4.
Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C . Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016; 8(343):343re2. DOI: 10.1126/scitranslmed.aaf6086. View

5.
Husseini G, Pitt W . Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008; 60(10):1137-52. PMC: 2490710. DOI: 10.1016/j.addr.2008.03.008. View